{
    "nctId": "NCT00080262",
    "briefTitle": "Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)",
    "officialTitle": "Phase II Study of Novel Epothilone (BMS-247550) in Patients With MBC Who Are Refractory to an Anthracycline, a Taxane, and Capecitabine",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Metastases",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 125,
    "primaryOutcomeMeasure": "Response rate as determined by the IRRC",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients must have received all 3 drugs- an anthracycline, taxane, and capecitabine (alone or in combination) and be resistant\n* No more than 3 prior chemotherapy regimens in the metastatic setting\n* Must have at least one target lesion that is radiographically measurable\n* Good performance status\n* No history of or current brain or leptomeningeal disease",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}